Last reviewed · How we verify
Randomized Evaluation of Beta Blocker and ACEI/ARB Treatment in MINOCA Patients - MINOCA-BAT
Myocardial infarction with non-obstructive coronary arteries" (MINOCA) occurs in 5-10% of all patients with AMI. There are neither any randomized clinical trials in MINOCA patients evaluating effects of secondary preventive treatments proven beneficial in patients with classic AMI, nor any treatment guidelines. The primary objective of this multi-national, multi-center pragmatic randomized clinical trial is to determine whether oral beta-blockade compared to no oral beta-blockade, and whether Angiotensin Converting Enzyme Inhibitors (ACEI/ Angiotensin Receptor Blockers (ARB) compared to no ACEI/ARB, reduce the composite endpoint of death of any cause and readmission because of AMI, ischemic stroke or heart failure in patients discharged with myocardial infarction with non-obstructive coronary artery disease (MINOCA) and with no clinical signs of heart failure and with left ventricular (LV) systolic ejection fraction ≥40%.
Details
| Lead sponsor | Uppsala University |
|---|---|
| Phase | PHASE4 |
| Status | TERMINATED |
| Enrolment | 198 |
| Start date | Sun Dec 16 2018 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Tue Aug 22 2023 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Myocardial Infarction With Non-obstructive Coronary Arteries
Interventions
- Beta blocker
- ACEI
- ARB
Countries
New Zealand, Sweden, Norway, Australia, Spain